Akebia Therapeutics (AKBA) Scheduled to Post Quarterly Earnings on Thursday

Akebia Therapeutics (NASDAQ:AKBA) will be posting its quarterly earnings results on Thursday, March 7th.

Akebia Therapeutics Stock Performance

NASDAQ AKBA traded down $0.11 on Wednesday, hitting $1.49. 3,938,478 shares of the stock were exchanged, compared to its average volume of 2,264,613. The stock has a fifty day moving average price of $1.51 and a two-hundred day moving average price of $1.24. The firm has a market capitalization of $296.32 million, a P/E ratio of -4.63 and a beta of 0.78. Akebia Therapeutics has a 52-week low of $0.49 and a 52-week high of $1.84.

Insider Activity

In other Akebia Therapeutics news, CEO John P. Butler sold 46,489 shares of the business’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $1.68, for a total value of $78,101.52. Following the completion of the transaction, the chief executive officer now directly owns 2,128,883 shares in the company, valued at $3,576,523.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO John P. Butler sold 46,489 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $1.68, for a total transaction of $78,101.52. Following the sale, the chief executive officer now owns 2,128,883 shares in the company, valued at $3,576,523.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Steven Keith Burke sold 24,311 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $1.68, for a total value of $40,842.48. Following the sale, the senior vice president now owns 711,376 shares in the company, valued at approximately $1,195,111.68. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 187,893 shares of company stock valued at $300,598. 3.84% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Akebia Therapeutics

A number of large investors have recently bought and sold shares of the company. Northern Trust Corp boosted its position in Akebia Therapeutics by 2.7% in the 4th quarter. Northern Trust Corp now owns 310,368 shares of the biopharmaceutical company’s stock worth $385,000 after purchasing an additional 8,247 shares in the last quarter. HighTower Advisors LLC boosted its position in Akebia Therapeutics by 18.4% in the 1st quarter. HighTower Advisors LLC now owns 70,350 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 10,925 shares in the last quarter. FMR LLC boosted its position in Akebia Therapeutics by 4.0% in the 3rd quarter. FMR LLC now owns 638,090 shares of the biopharmaceutical company’s stock worth $727,000 after purchasing an additional 24,500 shares in the last quarter. Swiss National Bank boosted its position in Akebia Therapeutics by 7.8% in the 1st quarter. Swiss National Bank now owns 393,085 shares of the biopharmaceutical company’s stock worth $282,000 after purchasing an additional 28,300 shares in the last quarter. Finally, UBS Group AG boosted its position in Akebia Therapeutics by 49.7% in the 1st quarter. UBS Group AG now owns 87,975 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 29,220 shares in the last quarter. Hedge funds and other institutional investors own 27.04% of the company’s stock.

Analyst Ratings Changes

AKBA has been the subject of a number of recent analyst reports. BTIG Research reissued a “buy” rating and set a $4.00 target price on shares of Akebia Therapeutics in a research note on Wednesday, November 29th. HC Wainwright boosted their target price on shares of Akebia Therapeutics from $3.75 to $5.00 and gave the company a “buy” rating in a research note on Friday, November 17th.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients.